Trial finds combination therapy can benefit those at final stage of disease
Combining the newly developed drug palbociclib with hormone therapy substantially extends the lives of women with advanced breast cancer, scientists announced yesterday.
Women with metastatic cancer who were given the combination therapy lived seven months longer than those who were treated with hormones alone. And in women who had previously responded to hormone therapy, these extended survival times reached an average of 10 months.
This post was syndicated from Health | The Guardian. Click here to read the full text on the original website.